Recruiting

Irreversible Electroporation

Sponsor:

University of Louisville

Code:

NCT02674100

Conditions

Pancreatic Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Registry

Study Details

Brief summary:

The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions.

The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have.

Conditions

Pancreatic Cancer

Study ID

NCT02674100

Start date

Jan, 2016

Status verified date

Dec, 2024

Completion date

Jan, 2030

Anticipated

Primary completion date

Jan, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adult patients (greater than 18 years of age) diagnosed with pancreatic cancer that are eligible for soft tissue ablation per the treating physician.

Exclusion Criteria:

  • Have a cardiac pacemaker or ICD implant
  • Non-removable implants with metal parts near target lesion
  • Myocardial infarction within 3 months prior to enrollment
  • Not suitable for general endotracheal anesthesia

Study Design

Enrollment

500 participants

Anticipated

Interventions and Outcome Measures

Interventions

Registry

Primary outcome measure

  • Adverse Events [ Time Frame: Up to 5 years ]

Central Contacts and Locations

Central contacts

Robert Martin, MD, PhD

502-629-3355robert.martin@louisville.edu

Locations

University of Alabama Birmingham

Recruiting

Birmingham, Alabama, United States, 35233

Contacts

John Christein, MD

jchristein@uabmc.edu

University of California San Diego

Recruiting

San Diego, California, United States, 92093

Contacts

Rebekah White, MD

reqhite@ucsd.edu

University of Colorado

Recruiting

Denver, Colorado, United States, 80309

Contacts

Ana Gleisner

ana.gleisner@ucdenver.edu

University of South Florida

Recruiting

Tampa, Florida, United States, 33620

Contacts

Rachel Karlnoski

rkarlnos@health.usf.edu

Augusta University

Recruiting

Augusta, Georgia, United States, 30912

Contacts

Edward Kruse, MD

ekruse@gru.edu

University of Louisville

Recruiting

Louisville, Kentucky, United States, 40202

Principal Investigator:

Robert Martin, MD

Johns Hopkins Hospital

Recruiting

Baltimore, Maryland, United States, 21218

Contacts

Matthew Weiss, MD

mweiss5@jhmi.edu

Atlantic Health

Recruiting

Millburn, New Jersey, United States, 07041

Contacts

Kai Bickenbach, MD

kai.beckenbach@atlantichealth.org

Northwell Health Cancer Institute

Recruiting

Lake Success, New York, United States, 11042

Contacts

Gary Deutsch, MD

gdeutsch@northwell.edu

Gibbs Cancer Research, Spartanburg Regional Healthcare System

Recruiting

Spartanburg, South Carolina, United States, 29303

Contacts

Heather Farmer

hfarmer@gibbscc.org

Methodist Digestive Institute

Recruiting

Dallas, Texas, United States, 75203

Contacts

Alejandro Mejia, MD

alejandromejia@mhd.com

McGill University

Recruiting

Montréal, Quebec, Canada

Contacts

Yifan Wang

yifan.wang3@mail.mcgill.ca

More Information

Sponsor

University of Louisville

Last update posted

Feb 25, 2025

Last verified

Dec, 2024

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Louisville on 2025-02-25.